JAZZ - Why Jazz Pharmaceuticals Stock Rose 13.3% in March
Jazz Pharmaceuticals (NASDAQ: JAZZ) , which specializes in neuroscience and oncology therapies, saw its stock rise 13.3% in March, according to data from S&P Global Market Intelligence . The stock began the month at $135.93 and never looked back, climbing to a high of $162.76 on March 25 and ending the month at $155.67, nearly $20 higher than it started.
Image Source: Getty Images
It's easy to see the catalyst for the stock's rise -- an impressive fourth-quarter and annual report released on March 1 that also included encouraging guidance for the rest of the year. The day after the report came out, the stock jumped 12.2%.
For further details see:
Why Jazz Pharmaceuticals Stock Rose 13.3% in March